Recently, BOC Sciences announced the completion of — antibody-drug conjugate (ADC) GMP manufacturing deployment to further advance the ADC manufacturing and clinical applications of its partners.
Based on this project, BOC Sciences is able to perform scale-up, process development, and GMP manufacturing, and produce ADCs for preclinical and early clinical research. This ADC manufacturing project is a supplement to BOC Sciences's existing GMP manufacturing capabilities and can be used for large-scale production and manufacturing of efficient ADC product intermediates and effective linkers, cytotoxins, etc.
This project is a key point of BOC Sciences's comprehensive layout of the ADC platform plan, which will greatly expand the group's ADC chemical solutions. Obviously, there are kinds of advantages of cooperating with the established CDMO on the ADC project: having experience in various ADC technologies; having developed effective processes for technology transfer and manufacturing; having manufacturing expertise, especially GMP batches manufacturing expertise; understanding ADC's regulatory approach.
About BOC Sciences
BOC Sciences is a leading drug development and manufacturing and technology platform-based company that provides efficient, flexible, and high-quality solutions to global partners. BOC Sciences supports the development and manufacturing of biopharmaceutical products by providing proprietary technologies, services, and products. In the development of antibody-drug conjugates (ADCs), BOC Sciences provides the following services, products, and technologies:
Contract ADC conjugation research service;
Proprietary site-specific conjugation technology and novel payload developed for ADC;
ADC linker, payload, and combined linker payload;
Contract procedure development and GMP production of biopharmaceuticals (including ADC products for pre-clinical and clinical research);
Characterization and analysis services of ADC products.
For more information, please visit: https://adc.bocsci.com.
Release ID: 89001387